Related Experiment Video
Updated: Sep 19, 2025

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
Published on: June 14, 2021
Allogenic Transplantation of RPE Strips Lacking MHC Class II Can Avoid Rejection in Nonhuman Primate Eyes
Atsuta Ozaki1,2,3, Sunao Sugita1,4,5, Masaaki Ishida6
1Kobe City Eye Hospital, Hyogo, Japan.
Purpose:
We previously reported that suspensions of CIITA-/- monkey induced pluripotent stem cell-derived retinal pigment epithelium (moiPSC-RPE) that lacks expression of major histocompatibility complex (MHC) class Ⅱ avoided rejection without systemic immunosuppression. RPE strips represent a novel graft formulation for RPE impairment diseases that may enable mass engraftment but potentially increase rejection risk. This study evaluated host immune responses to allogeneic CIITA+/+ and CIITA-/- moiPSC-RPE strips in MHC-mismatched transplantation in monkey eyes with RPE damage, without systemic immunosuppression.
Methods:
RPE strips were generated from CIITA+/+ and CIITA-/- moiPSC-RPE. Following RPE ablation using a microsecond pulse laser, two RPE strips were transplanted into each eye at 1- to 3-week intervals. One monkey received CIITA+/+ moiPSC-RPE strips, while another received CIITA-/- moiPSC-RPE strips. Graft status was monitored through routine ophthalmic examinations, and immunohistologic evaluation was conducted after 5 months.
Results:
Fluorescein angiography revealed evident leakage in eyes with CIITA+/+ RPE strips beginning 1 to 2 months posttransplantation, with optical coherence tomography showing bulging at the graft site, indicating immune cell accumulation. Immunostaining confirmed the presence of immune cells (CD4, CD8, Iba1, IFN-γ, MHC class II, and CD20) at CIITA+/+ RPE strip grafts. In contrast, CIITA-/- RPE strip transplants showed no signs of rejection in either eye over 5 months and minimal immune cell presence at the graft site.
Conclusions:
Allogeneic transplantation of CIITA-/- RPE strips may reduce rejection risk in RPE-ablated disease model eyes, suggesting potential clinical benefits of MHC class II-deficient RPE grafts, particularly for diseases with inflammatory pathology.

